CervoMed Inc. has received a U.S. patent allowing exclusive use of its drug candidate neflamapimod for treating pure dementia with Lewy bodies (DLB) without Alzheimer's-like tau pathology. This patent protection extends potentially until 2042, covering a treatment area with no current approved therapies in the U.S. or EU. The company recently completed a Phase 2b trial and is aligned with the FDA on a potential registration path, with plans for a Phase 3 trial pending partnership or financing. CervoMed is also advancing trials for other brain disorders, including frontotemporal disorders and ALS.
Bitcoin miners are experiencing declining revenue as the network's hash rate and mining difficulty fall, reflecting a shift of miners into AI infrastructure. Despite this stress, miners are accumulating Bitcoin, with reserves increasing by 1%, signal...
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
